With a one year PEG ratio of 0.27, Gw Pharmaceuticals Plc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 5.07% of US stocks.
With a price/earnings ratio of 118.4, Gw Pharmaceuticals Plc P/E ratio is greater than that of about 94.92% of stocks in our set with positive earnings.
Revenue growth over the past 12 months for Gw Pharmaceuticals Plc comes in at 87.98%, a number that bests 93.57% of the US stocks we're tracking.
If you're looking for stocks that are quantitatively similar to Gw Pharmaceuticals Plc, a group of peers worth examining would be NTGR, VRNT, PCTI, NXGN, and YELP.
GWPH's SEC filings can be seen here. And to visit Gw Pharmaceuticals Plc's official web site, go to www.gwpharm.com.
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. It operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company was founded in 1998 and is based in Cambridge, the United Kingdom.
Until the end of the first quarter of 2019, you could have thrown a dart at a list of publicly traded pot stocks and likely come out a significant winner. With people stuck at home, lawn and garden projects are there to keep them busy.
GW Pharmaceuticals (GWPH) announces strategy for bringing its pipeline product nabiximols to the U.S. market.The company plans to commence a Phase 3 clinical program, including, MS Spasticity Clinical program, Spinal Cord Injury spasticity program and Post Traumatic Stress Disorder program which will provide multiple opportunities for an NDA submission, as early as...
The marijuana industry includes companies directly related to the research, development, and distribution of cannabis products, as well as companies that indirectly support these operations. As a growing number of U.S. states and countries around the world legalize marijuana in one or more forms, traditional stock market indices like the Nasdaq have begun to include more companies from the marijuana industry. Now, companies like Village Farms International Inc. (VFF) and OrganiGram Holdings Inc. (OGI) are being traded on the Nasdaq and other U.S. exchanges rather than the over-the-counter market. Many companies in the young industry are losing money due both to the economic downturn and as they invest heavily to focus on rapidly expanding revenue.
You might pick pot producers, companies with just slight exposure to the industry, or medical marijuana stocks. The stock's been producing some impressive sales numbers over the past year, but for risk-averse investors, it may be too dependent on the success of just one drug. One danger of investing in the pharmaceutical industry is that a stock's success often hinges on just one drug.